VMValentina Milazzo

Valentina Milazzo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Valentina Milazzo has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extended dual antiplatelet therapy after acute myocardial infarction. Current evidence and future perspectives

    by Nicola Cosentino, Jeness Campodonico, Valentina Milazzo, Katia Celentano, Marco Moltrasio, Pompilio Faggiano, Giancarlo Marenzi

    Patients with acute myocardial infarction (AMI) are at increased risk of recurrent ischemic events after hospital discharge, despite optimal medical therapy. Current practice guidelines strongly encourage the early assessment of the residual ischemic risk in post-AMI patients, in order to identify those who may benefit from a prolonged dual antiplatelet therapy. To this end, some scoring systems have been proposed. However, most scores were developed for patients with stable coronary artery disease undergoing percutaneous coronary intervention. Moreover, nearly all failed to be implemented in everyday clinical practice, probably because of the perceived complexity due to the large number of incorporated variables. Therefore, the identification of the ideal AMI patient who can benefit from a prolonged (beyond 1 year after the index event) dual antiplatelet therapy remains to be clarified, especially when the bleeding risk associated with such therapy is considered. In this review, we summarize the current evidence on the prolonged use of dual antiplatelet therapy after AMI, with a special focus on recent advances regarding the identification of high-risk patients who may derive a favorable net clinical benefit from such a therapeutic strategy.


  • Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Acute Myocardial Infarction: A Prospective Study

    by Giancarlo Marenzi, Nicola Cosentino, Valentina Milazzo, Monica De Metrio, Milena Cecere, Susanna Mosca, Mara Rubino, Jeness Campodonico, Marco Moltrasio, Ivana Marana, et al.

    OBJECTIVE Acute hyperglycemia is a powerful predictor of poor prognosis in acute myocardial infarction (AMI), particularly in patients without diabetes. This emphasizes the importance of an acute glycemic rise rather than glycemia level at admission alone. We investigated in AMI whether the combined evaluation of acute and chronic glycemic levels, as compared with admission glycemia alone, may have a better prognostic value. RESEARCH DESIGN AND METHODS We prospectively measured admission glycemia and estimated average chronic glucose levels (mg/dL) by the following formula: [(28.7 × glycosylated hemoglobin %) − 46.7], and calculated the acute-to- chronic (A/C) glycemic ratio in 1,553 consecutive AMI patients (mean ± SD age 67 ± 13 years). The primary end point was the combination of in-hospital mortality, acute pulmonary edema, and cardiogenic shock. RESULTS The primary end point rate increased in parallel with A/C glycemic ratio tertiles (5%, 8%, and 20%, respectively; P for trend P < 0.0001). At multivariable analysis, A/C glycemic ratio remained an independent predictor of the primary end point and of troponin I peak value, even after adjustment for major confounders. At reclassification analyses, A/C glycemic ratio showed the best prognostic power in predicting the primary end point as compared with glycemia at admission in the entire population (net reclassification improvement 12% [95% CI 4–20%]; P = 0.003) and, particularly, in patients with diabetes (27% [95% CI 14–40%]; P < 0.0001). CONCLUSIONS In AMI patients with diabetes, A/C glycemic ratio is a better predictor of in-hospital morbidity and mortality than glycemia at admission.


  • Open Access

    Extracorporeal ultrafiltration for acute heart failure: patient selection and perspectives

    by Valentina Milazzo, Nicola Cosentino, Giancarlo Marenzi

    Most patients presenting with acute heart failure (AHF) show signs and symptoms of fluid overload, which are closely associated with short-term and long-term outcomes. Ultrafiltration is an extremely appealing strategy for patients with AHF and concomitant overt fluid overload not fully responsive to diuretic therapy. However, although there are several theoretical beneficial effects associated with ultrafiltration, published reports have shown controversial findings. Differences in selection of the study population and in ultrafiltration indications and protocols, and high variability in the pharmacologic therapy used for the control group could explain some of these conflicting results. Here, we aimed to provide an overview on the current medical evidence supporting the use of ultrafiltration in AHF, with a special focus on the identification of potential candidates who may benefit the most from this therapeutic option.


  • Renal replacement therapy in patients with acute myocardial infarction: Rate of use, clinical predictors and relationship with in-hospital mortality

    by Giancarlo Marenzi, Nicola Cosentino, Andrea Marinetti, Antonio M. Leone, Valentina Milazzo, Mara Rubino, Monica De Metrio, Angelo Cabiati, Jeness Campodonico, Marco Moltrasio, et al.


  • Open Access

    Vitamin D and acute myocardial infarction

    by Valentina Milazzo, Monica De Metrio, Nicola Cosentino, Giancarlo Marenzi, Elena Tremoli

    Vitamin D deficiency is a prevalent condition, cutting across all ethnicities and among all age groups, and occurring in about 30%-50% of the population. Besides vitamin D established role in calcium homeostasis, its deficiency is emerging as a new risk factor for coronary artery disease. Notably, clinical investigations have suggested that there is an association between hypovitaminosis D and acute myocardial infarction (AMI). Not only has it been linked to incident AMI, but also to increased morbidity and mortality in this clinical setting. Moreover, vitamin D deficiency seems to predispose to recurrent adverse cardiovascular events, as it is associated with post-infarction complications and cardiac remodeling in patients with AMI. Several mechanisms underlying the association between vitamin D and AMI risk can be involved. Despite these observational and mechanistic data, interventional trials with supplementation of vitamin D are controversial. In this review, we will discuss the evidence on the association between vitamin D deficiency and AMI, in terms of prevalence and prognostic impact, and the possible mechanisms mediating it. Further research in this direction is warranted and it is likely to open up new avenues for reducing the risk of AMI.


  • Open Access

    Diagnostic and Prognostic Utility of Circulating Cytochrome c in Acute Myocardial Infarction

    by Giancarlo Marenzi, Nicola Cosentino, Jasper Boeddinghaus, Mirella Trinei, Marco Giorgio, Valentina Milazzo, Marco Moltrasio, Daniela Cardinale, Maria Teresa Sandri, Fabrizio Veglia, et al.

    Rationale:: In contrast to cardiomyocyte necrosis, which can be quantified by cardiac troponin, functional cardiomyocyte impairment, including mitochondrial dysfunction, has escaped clinical recognition in acute myocardial infarction (AMI) patients. Objective:: To investigate the diagnostic accuracy for AMI and prognostic prediction of in-hospital mortality of cytochrome c . Methods and Results:: We prospectively assessed cytochrome c serum levels at hospital presentation in 2 cohorts: a diagnostic cohort of patients presenting with suspected AMI and a prognostic cohort of definite AMI patients. Diagnostic accuracy for AMI was the primary diagnostic end point, and prognostic prediction of in-hospital mortality was the primary prognostic end point. Serum cytochrome c had no diagnostic utility for AMI (area under the receiver-operating characteristics curve 0.51; 95% confidence intervals 0.44–0.58; P =0.76). Among 753 AMI patients in the prognostic cohort, cytochrome c was detectable in 280 (37%) patients. These patients had higher in-hospital mortality than patients with nondetectable cytochrome c (6% versus 1%; P c , as compared with those with nondetectable cytochrome c (11% versus 1%; P c remained a significant independent predictor of in-hospital mortality (odds ratio 3.0; 95% confidence interval 1.9–5.7; P P =0.02). Conclusions:: Cytochrome c serum concentrations do not have diagnostic but substantial prognostic utility in AMI.


  • Brain natriuretic peptide in acute myocardial infarction

    by Marco Moltrasio, Nicola Cosentino, Monica De Metrio, Mara Rubino, Angelo Cabiati, Valentina Milazzo, Andrea Discacciati, Ivana Marana, Alice Bonomi, Fabrizio Veglia, et al.

    Cardiac and renal functions are major independent predictors of outcomes in both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). As B-type natriuretic peptide (BNP) seems to be a major mediator in the cross-talk between heart and kidneys, we aimed at evaluating its capacity to reflect cardiac and renal function in patients with STEMI and NSTEMI. We measured BNP plasma levels at hospital admission in 619 patients with STEMI (n = 346) and NSTEMI (n = 273), grouped according to left ventricular ejection fraction (LVEF; > or ≤40%) and estimated glomerular filtration rate (eGFR; > or ≤ 60 ml/min/1.73 m). Median BNP values were 82 (38-186), 121 (40-342), 219 (80-685), and 474 (124-1263) pg/ml in patients with normal LVEF and eGFR (n = 347), with LVEF 40% or less and eGFR higher than 60 ml/min/1.73 m (n = 120), with LVEF higher than 40% and eGFR 60 ml/min/1.73 m or less (n = 86), and with combined LVEF and eGFR reductions (n = 66), respectively (P < 0.0001). At general linear model, both LVEF higher than 40% (P < 0.0001) and eGFR 60 ml/min/1.73 m or less (P < 0.0001) independently predicted BNP values. At multivariable analysis, BNP, LVEF 40% or less, and eGFR 60 ml/min/1.73 m or less were found to be independent predictors of the combined end point of in-hospital death, cardiogenic shock, need for renal replacement therapy, or mechanical ventilation (P = 0.003; P < 0.0001; P = 0.01, respectively). BNP plasma levels are closely related to LVEF and eGFR at hospital admission, in both STEMI and NSTEMI patients. Future studies should investigate whether BNP levels can summarize in a single parameter the prognostic information provided separately by cardiac and renal dysfunction.


  • Open Access

    Acute Kidney Injury Definition and In‐Hospital Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for ST‐Segment Elevation Myocardial Infarction

    by Giancarlo Marenzi, Nicola Cosentino, Marco Moltrasio, Mara Rubino, Gabriele Crimi, Stefano Buratti, Marco Grazi, Valentina Milazzo, Alberto Somaschini, Rita Camporotondo, et al.

    Background: Acute kidney injury (AKI) has been associated with increased mortality in ST ‐segment elevation myocardial infarction. We compared the mortality predictive accuracy of the 3 AKI definitions used most widely for patients with ST ‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Methods and Results: We included 3771 patients with ST ‐segment elevation myocardial infarction treated with primary percutaneous coronary intervention at 2 Italian hospitals. AKI incidence was evaluated according to creatinine increases of ≥25% ( AKI ‐25), ≥0.3 mg/dL ( AKI ‐0.3), and ≥0.5 mg/dL ( AKI ‐0.5). The primary end point was in‐hospital mortality. Overall, 557 (15%), 522 (14%), and 270 (7%) patients developed AKI ‐25, AKI ‐0.3, and AKI ‐0.5, respectively ( P P P P =0.01] and +8% versus AKI ‐25 [ P =0.05]). Conclusions: Each AKI definition significantly improved the mortality prediction beyond major clinical variables. AKI ‐0.5 showed a mortality discrimination advantage, suggesting it should be the preferred definition in studies addressing ST ‐segment elevation myocardial infarction and focusing on short‐term mortality.


  • B-type natriuretic peptide levels in patients with pericardial effusion undergoing pericardiocentesis

    by Gianfranco Lauri, Chiara Rossi, Mara Rubino, Nicola Cosentino, Valentina Milazzo, Ivana Marana, Angelo Cabiati, Marco Moltrasio, Monica De Metrio, Marco Grazi, et al.


  • Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

    by Giancarlo Marenzi, Nicola Cosentino, Sarah Cortinovis, Valentina Milazzo, Mara Rubino, Angelo Cabiati, Monica De Metrio, Marco Moltrasio, Gianfranco Lauri, Jeness Campodonico, et al.